Report cover image

Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18679485

Description

Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2024



DelveInsight’s, “DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in DP1 Receptor (Prostaglandin D2 receptor) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Understanding

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview

Prostaglandin D2 receptor is a 395 amino acid, 43 kDa G-protein-coupled receptors. PGD2 is released following activation of the immune system, which can be either non-allergen- or allergen-dependent. Binding of PGD2 to the DP2 receptor on immune cells induces a myriad of pro-inflammatory downstream effects, which significantly contribute to the recruitment, activation and/or migration of TH2 cells, ILC2, and eosinophils. PGD2 produced by mast cells might provide an essential link between the early phase and late-phase allergic responses and such antagonism of PGD2 provides an attractive target for therapeutic intervention. Several selective, orally active, DP2 receptor antagonists are being developed for the treatment of allergic disorders.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence DP1 Receptor (Prostaglandin D2 receptor) Antagonist R&D. The therapies under development are focused on novel approaches for DP1 Receptor (Prostaglandin D2 receptor) Antagonist.
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Emerging Drugs Chapters

This segment of the DP1 Receptor (Prostaglandin D2 receptor) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Emerging Drugs
  • BGE-175: BioAge Labs
BGE-175 is an orally administered small-molecule based inhibitor of the prostaglandin D2 (PGD2) DP1 signaling pathway. The drug is in phase II clinical studies for the treatment of Covid-19 infections. In January 2021, Shionogi announced that it has concluded a license agreement with BioAge Labs. With this agreement, Shionogi grants BioAge exclusive U.S. and European rights to develop and commercialize BGE-175 for COVID-19 treatment. In addition, Shionogi grants BioAge exclusive rights to negotiate a license for additional indications. Under this agreement, Shionogi will receive an upfront payment and milestones according to future development, as well as royalties on sales if BGE-175 is successfully commercialized.
  • SLS 008: Seelos Therapeutics
SLS 008 is a small molecule, orally-bioavailable antagonist of the prostaglandin D2 receptor. The drug is in preclinical studies for the treatment of asthma, atopic dermatitis, and oesophagitis.

Further product details are provided in the report……..

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Therapeutic Assessment

This segment of the report provides insights about the different DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on DP1 Receptor (Prostaglandin D2 receptor) Antagonist
There are approx. 8+ key companies which are developing the DP1 Receptor (Prostaglandin D2 receptor) Antagonist. The companies which have their DP1 Receptor (Prostaglandin D2 receptor) Antagonist drug candidates in the most advanced stage, i.e. Phase II include, BioAge Labs.
  • Phases
DelveInsight’s report covers around 8+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
DP1 Receptor (Prostaglandin D2 receptor) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Report Insights
  • DP1 Receptor (Prostaglandin D2 receptor) Antagonist Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs?
  • How many DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for DP1 Receptor (Prostaglandin D2 receptor) Antagonist?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for DP1 Receptor (Prostaglandin D2 receptor) Antagonist and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • CSPC ZhongQi Pharmaceutical Technology
  • BioAge Labs
  • Novartis
  • Chiesi Farmaceutici
  • Idorsia Pharmaceuticals
  • Seelos Therapeutics
  • Sunshine Lake Pharma
Key Products
  • CSPCHA-115
  • Asapiprant
  • Fevipiprant
  • Timapiprant
  • ACT-774312
  • SLS 008
  • Litapiprant

Table of Contents

60 Pages
Introduction
Executive Summary
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
DP1 Receptor (Prostaglandin D2 receptor) Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
DP1 Receptor (Prostaglandin D2 receptor) Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Fevipiprant: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BGE-175: BioAge Labs
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CSPCHA-115: CSPC ZhongQi Pharmaceutical Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SLS 008: Seelos Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Companies
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Products
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Unmet Needs
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Market Drivers and Barriers
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Future Perspectives and Conclusion
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Analyst Views
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us